ZNTL

1.3600.00%
IB

Ingmar Bruns

Chief Medical Officer

Dr. Ingmar Bruns, M.D., Ph.D., serves as Chief Medical Officer at Zentalis Pharmaceuticals, Inc since November 2024. Dr. Bruns joined the Zentalis Pharmaceuticals, Inc. in November 2024. He served as Chief Medical Officer of Trillium Therapeutics Inc. since November 2, 2020 until November 17, 2021. Dr. Bruns served as Senior Vice President and Head of Clinical Development at Pieris Pharmaceuticals, Inc. He served as Vice President of Clinical Development at Pieris Pharmaceuticals, Inc. since October 12, 2017. Prior to Pieris, from 2013 to October 2017, Dr. Bruns led clinical development of several high priority oncology assets at Bayer Pharmaceuticals. Dr. Bruns served as an attending hematologist and oncologist as well as a basic, translational and clinical researcher at the University Hospital of Dusseldorf in Germany and Albert Einstein College of Medicine in New York. Dr. Bruns is an accomplished physician and wealth of oncology & hematology experience, a deep science background and a strong clinical development acumen. Dr. Bruns has authored over 50 papers in the field of hematology and oncology. Dr. Bruns has authored over 50 publications in the field of hematology and oncology, including several lead authorships in high impact journals such as Nature Medicine, Blood and Leukemia. He received his M.D. and Ph.D. from the University of Lubeck in Germany.

Positions